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In this study, designed to evaluate the efﬁcacy of lurasidone as adjunctive therapy with lithium or val-
proate, patients with bipolar I depression were randomized to 6 weeks of double-blind treatment with
lurasidone (N ¼ 180) or placebo (N ¼ 176), added to background treatment with lithium or valproate. All
patients were treated with lithium or valproate for a minimum of 4 weeks prior to screening. This was
conﬁrmed either by prospective treatment after study enrolment (run-in cohort), or retrospectively, with
blood levels of lithium and valproate at screening (non-run-in cohort). Primary and key secondary
endpoints were change from baseline to week 6 on the Montgomery-Åsberg Depression Rating Scale
(MADRS) and depression severity score on the Clinical Global Impressions scale for use in bipolar illness
(CGI-BP-S), respectively. Treatment with lurasidone was associated with non-signiﬁcant improvement at
week 6 vs. placebo for the MADRS total score (11.8 vs 10.4; P ¼ 0.176), and the CGI-BP-S score (1.36
vs 1.13; P ¼ 0.095). Signiﬁcant separation from placebo was observed from weeks 2e5 for the MADRS
and weeks 3e5 for the CGI-BP-S. Improvement in the placebo-subtracted MADRS total score was notably
larger at week 6 for the non-run-in cohort compared to the run-in cohort (LS mean difference in
endpoint change scores, 4.6; P ¼ 0.009). Adverse events most frequently reported for lurasidone were
akathisia, somnolence, and extrapyramidal side effects. In conclusion, lurasidone adjunctive with lithium
or valproate demonstrated signiﬁcant improvement in depressive symptoms based on the MADRS from
weeks 2e5 but not at the primary week 6 endpoint.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Medications for the treatment of bipolar depression are often
used in combination. Multiple large scale surveys of prescribing
practices indicate that more than 75% of patients with bipolar
depression receive at least 2 medications, and more than one-third
receive 3 or more (Goldberg et al., 2009; Haeberle et al., 2012; Greil
et al., 2012). Over the past decade there has been a marked increase
in the use of atypical antipsychotics for the treatment of bipolar
depression. Up to 60% of patients treated with atypical antipsy-
chotics for bipolar depression are on adjunctive therapy, mostInc., One Bridge Plaza North,
oebel).
euticals at the time this work
n South Plainﬁeld, NJ, USA.
Ltd. This is an open access article ucommonly with either mood stabilizers or standard antidepres-
sants (Goldberg et al., 2009; Haeberle et al., 2012; Greil et al., 2012;
Hooshmand et al., 2014; Ketter et al., 2015).
Although combination treatment is common in patients with
bipolar depression, few controlled trials have been reported to
support such use. The limited availability of evidence-based op-
tions for the acute treatment of patients with bipolar depression
(Ostacher et al., 2015) is reﬂected in the lack of consensus in many
treatment guidelines which recommend as ﬁrst-line treatment a
wide range of both monotherapies (e.g., quetiapine, lithium,
lamotrigine) and combination therapies (e.g., atypicals þ mood
stabilizers, atypicals þ antidepressants, antidepressants þ mood
stabilizers; Nivoli et al., 2011; Pacchiarotti et al., 2013).
Lurasidone is the only psychotropic agent that has demon-
strated efﬁcacy as an adjunctive therapy, with lithium or valproate,
for the acute treatment of bipolar depression, based on positive
results from a placebo-controlled trial (Loebel et al., 2014a). Innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mood stabilizers in bipolar depression have been negative (Thase
et al., 2008; Sachs et al., 2011).
The aim of the current study was to further evaluate the short-
term efﬁcacy and safety of lurasidone as adjunctive therapy with
lithium or valproate in patients with bipolar depression. In both
lurasidone bipolar depression adjunctive treatment studies, pa-
tients were required to have failed at least 4 weeks of adequate
treatment with either lithium or valproate prior to randomization.
The current study established inadequate response to mood sta-
bilizer treatment based on either prospective treatment with
lithium or valproate after study enrolment (run-in cohort), or
retrospectively using several conﬁrmatory methods (non-run-in
cohort), allowing for a pre-planned secondary analysis of within-
study comparison of the impact of these case ascertainment
approaches.
2. Methods
2.1. Patients
This multiregional study enrolled outpatients, 18e75 years of
age (inclusive), diagnosed with bipolar I disorder who were expe-
riencing a major depressive episode (DSM-IV-TR criteria, 4 weeks
and <12 months in duration), with a history of at least one lifetime
bipolar manic or mixed manic episode either with rapid cycling
(limited to <8 episodes in the past 12 months) or without rapid
cycling, and without psychotic features. Diagnosis was conﬁrmed
by the Mini International Neuropsychiatric Interview (Sheehan
et al., 1998) and the Bipolarity Index (Sachs, 2004). A Mont-
gomery-Åsberg Depression Rating Scale (MADRS;Montgomery and
Åsberg, 1979) score 20 and a Young Mania Rating Scale (YMRS;
Young et al., 1978) score 12 were required at both screening and
baseline.
Patients were excluded if they demonstrated a reduction of
25% inMADRS total score between screening and baseline; scored
4 on MADRS item 10 (suicidal thoughts) at screening or baseline;
were judged to be at imminent risk of suicide or injury to self or
others; had been hospitalized for a manic or mixed episode within
the 60 days prior to randomization; had received treatment with
antidepressants within 3 days, ﬂuoxetine within 28 days, an MAO
inhibitor within 21 days of randomization, or clozapine within 120
days of randomization; had an acute or unstable medical condition;
had a history of alcohol or substance abuse (past 3 months) or
dependence (12 months); or had a history of non-response to 3
adequate (6-week) trials of an antidepressant (with or without
mood stabilizers) during the current depressive episode.
The studywas approved by an institutional review board at each
investigational site and was conducted in accordance with the In-
ternational Conference on Harmonisation Good Clinical Practices
guidelines and with the ethical principles of the Declaration of
Helsinki. All patients who entered the study reviewed and signed
an informed consent document explaining study procedures and
potential risks before study entry. An independent data and safety
monitoring board reviewed andmonitored subject data throughout
the study.
2.2. Study cohorts
All patients were required to have been treated for at least 28
days with lithium or valproate prior to screening, based on inter-
view of the patient and a reliable informant, chart records, and
documented blood levels within the protocol-speciﬁed therapeutic
range at the time of screening (0.6e1.2 mEq/L for Li; 50e125 mg/mL
for VPA). A variable length (but 8 weeks), prospective run-inperiod was utilized for all patients not meeting these criteria at
initial screening. Patients with less than 28 days of treatment with
lithium or valproate at initial screening were required to complete
the missing days of treatment in a prospective run-in period (run-
in cohort). Patients with lithium or valproate blood levels above or
below the protocol-speciﬁed therapeutic range at the time of
screening were required to achieve these levels at least once during
the run-in period. Patients meeting all entry criteria at screening
were permitted to be randomizedwithout further run-in treatment
(non-run-in cohort).
The study was approved by an Institutional Review Board at
each investigational site and was conducted in accordance with the
International Conference on Harmonisation Good Clinical Practice
guidelines and with the ethical principles of the Declaration of
Helsinki. An independent data and safety monitoring board
reviewed and monitored patient data throughout the study.
2.3. Study design
A total of 356 patients were randomized (currently treated
cohort, n ¼ 137; run-in treatment cohort, n ¼ 219) at 71 sites in
Europe (n¼ 106), North America (n¼ 162), Asia (n¼ 52), and South
America (n ¼ 36). This study was conducted between December
2010 and August 2012.
Patients underwent stratiﬁed randomization, based on treat-
ment with lithium or VPA, to either adjunctive lurasidone
20e120 mg/day or placebo in a 1:1 ratio via an Interactive Voice
Response System. A central randomization center used a computer-
generated list of random numbers to allocate study treatments.
None of the investigators, study staff or patients had access to the
randomization codes or list. Study medication was provided in
blister packs as identically matched tablets containing placebo, or
20 mg or 40 mg of lurasidone.
Lurasidone treatment was initiated at 20 mg/day on days 1e3,
increased to 40 mg/day on days 4e6, and then 60 mg/day on day 7.
After the ﬁrst week, lurasidone could be adjusted within the dose
range of 20e120 mg/day at weekly intervals, in 20 mg increments
or decrements, based on investigator judgment. Lurasidone (or
placebo) was taken once daily in the evening, with a meal or within
30 min after eating. The dose of mood stabilizer was adjusted to
maintain a serum level in the range of 0.6e1.2 mEq/L for lithium or
50e125 mg/mL for valproate throughout the study.
2.4. Concomitant medications
Treatment with anticholinergic agents, propranolol or amanti-
dine, was permitted as needed for movement disorders. As needed
treatment with lorazepam (2 mg/d) for anxiety, or with eszopi-
clone (3 mg/d), temazepam (30 mg/d), or zolpidem (12.5 mg/
d; for sleep) was permitted. Concomitant treatment for movement
disorders, anxiety or insomnia was not permitted within 8 h prior
to any psychiatric assessments.
2.5. Efﬁcacy assessments
Efﬁcacy assessments were obtained at baseline and weekly in-
tervals. The primary efﬁcacy endpoint was mean change from
baseline to week 6 in MADRS total score. The MADRS, a 10-item
scale with a total score that ranges from 0 to 60 (Montgomery
and Åsberg, 1979), was assessed at each study visit by a qualiﬁed
site-based rater; a second MADRS assessment was administered
and scored by computer as part of a quality control process
(Concordant Rater Systems, Boston, MA). The key secondary efﬁ-
cacy endpoint was mean change from baseline to week 6 in the
Clinical Global Impression-Bipolar Severity (CGI-BP-S) assessment,
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Additional secondary efﬁcacy assessments included the 16-item
Quick Inventory of Depressive Symptomatology, self-rated version
(QIDS-SR16; Rush et al., 2003), Hamilton Anxiety Rating Scale
(HAM-A; Hamilton, 1959), Sheehan Disability Scale (SDS; Sheehan,
1983), and Quality of Life Enjoyment and Satisfaction Questionnaire
e Short Form (Q-LES-Q-SF; Endicott et al., 1993).
2.6. Safety and tolerability evaluations
Safety and tolerability assessments included incidence and
severity of adverse events and administration of the Simpson-
Angus Scale (Simpson and Angus, 1970), Abnormal Involuntary
Movement Scale (Guy, 1976), and Barnes Akathisia Rating Scale
(Barnes, 1989) to evaluate movement disorders. Additional safety
evaluations included vital signs, laboratory tests, 12-lead ECG, and
physical examination. Treatment-emergent mania was deﬁned, a
priori, as a Young Mania Rating Scale (YMRS; Young et al., 1978)
score of 16 on any 2 consecutive visits, or at the ﬁnal assessment,
or an adverse event of mania or hypomania. Suicidal ideation and
behavior were assessed using the Columbia Suicide Severity Rating
Scale (C-SSRS; Posner et al., 2011).
2.7. Statistical analysis
The intent-to-treat population consisted of randomized patients
who received at least one dose of study medication and had at least
one post-baseline efﬁcacy assessment. The primary (MADRS) and
key secondary (CGI-BP-S) efﬁcacy endpoints were assessed using a
mixed model for repeated measures (MMRM) analysis including
ﬁxed effects for treatment, visit, pooled center, stratiﬁcation vari-
able (lithium or VPA), baseline score as a covariate, and a
treatment-by-visit interaction term. An unstructured covariance
matrix was used for within-patient correlation.
Changes from baseline in secondary efﬁcacy measures (QIDS-
SR16, HAM-A, SDS, Q-LES-Q-SR) were evaluated using an analysis of
covariance (ANCOVA) model using last observation carried forward
(LOCF) data that included terms for treatment, pooled center,
stratiﬁcation variable (lithium or VPA), and baseline score. Analyses
of secondary measures were not corrected for multiplicity.
A pre-planned analysis by cohort status (run-in versus non-run-
in) was conducted to determine the effect of ascertainment status
on the primary outcome measure. In this analysis, patients who
required any duration of prospective treatment with lithium or
valproate prior to randomization were classiﬁed as run-in cohort
patients; and patients who did not require run-in treatment (hav-
ing received adequate treatment with either lithium or valproate
for at least 4 weeks prior to screening) were classiﬁed as non-run-
in cohort patients. Core depressive symptomswere evaluated, post-
hoc, using the MADRS-6 subscale (Bech et al., 2002).
The proportion of responders (50 percent reduction from
baseline at LOCF endpoint in MADRS total) and remitters (MADRS
total 12) were compared between the lurasidone and placebo
groups using logistic regression. Cohen's d effect sizes (d) between
treatment groups were calculated as the difference in the change
score divided by the pooled standard deviation. Number needed to
treat to attain an additional responder was derived for the lur-
asidone group as follows: number needed to treat ¼ 1/(lurasidone
response rate e placebo response rate).
The safety population included all patients who were random-
ized and received at least one dose of studymedication. Descriptive
statistics were used to summarize safety variables including
treatment-emergent adverse events, vital signs, and laboratory
results. In addition, rank ANCOVA was used to analyze weight,
cholesterol, triglycerides, glucose, and insulin to compare changesfrom baseline between treatment groups. Changes from baseline in
the Simpson-Angus Scale, the Abnormal Involuntary Movement
Scale, and the Barnes Akathisia Rating Scale were analyzed using
ANCOVA-LOCF, with model terms for treatment, pooled center,
stratiﬁcation variable (lithium or VPA), and baseline score.
Sample size was determined based on a two-sample t-test, and
was powered at 90% to detect a 3.25-point difference in MADRS
change scores, with a common standard deviation of 9. The esti-
mated sample size of 340 included an additional 16 patients (5%) to
account for expected early attrition (patients randomized but with
no post-baseline efﬁcacy results).
3. Results
3.1. Baseline characteristics and patient disposition
A total of 748 patients were screened, of whom 356 (47.6%) were
randomized to 6 weeks of double-blind treatment (Fig. 1). Baseline
demographic and clinical characteristics were similar for the
adjunctive lurasidone and placebo groups (Table 1). Study comple-
tion rates were 82.2% for lurasidone and 79.5% for placebo (Fig. 1).
Among randomized patients, 38.5% were in the non run-in cohort
(on lithium or valproate for4 weeks prior to screening), and 61.5%
were in the run-in cohort (not on adequate lithium or valproate
prior to screening, but treated prospectively with lithium or val-
proate prior to randomization). In the non run-in cohort, themedian
duration of treatment with lithium and valproate prior to random-
ization was 4.4 months and 7.5 months, respectively. In the run-in
cohort, treatment with lithium or valproate was initiated at the
screen visit in 53.8% of patients; and 46.2%were receiving lithiumor
valproate at study entry, but required dose adjustments during the
prospective run-in period to achieve therapeutic plasma levels.
The mean daily dose of lurasidone during the study was 64.6 mg
and the mean modal daily dose was 74.5 mg. After completion of
ﬁxed titration to a lurasidone daily dose of 60 mg on day 7, 111/171
(64.8%) of patients increased to a dose of 80 mg/d, 68/171 (39.8%)
increased to a dose of 100 mg/d, and 34/171 (19.9%) increased to a
dose of 120 mg/d at some point during the remaining 5 weeks of
double-blind treatment.
At study entry, the proportion of patients receiving valproate
was higher than lithium for both the lurasidone (68.2%) and placebo
(65.7%) groups (Table 1). The mean baseline dose of lithium in the
lurasidone and placebo groups, respectively, was 932.6 mg/d and
942.5 mg/d; lithium concentrations were similar in the lurasidone
and placebo groups, respectively, at baseline (0.73 mEq/L vs. 0.82
mEq/L) and week 6 (0.68 mEq/L vs. 0.79 mEq/L). The mean baseline
dose of valproate in the lurasidone and placebo groups, respec-
tively, was 1067.5 mg/d and 1077.7 mg/d; valproate concentrations
were also similar at baseline (68.7 mg/mL vs. 73.6 mg/mL) and at
week 6 (67.8 mg/mL vs. 70.6 mg/mL).
3.2. Efﬁcacy
There was no signiﬁcant difference in least squares (LS) mean
change from baseline to week 6 in MADRS total scores for the
lurasidone versus placebo groups (11.8 vs. 10.4; P ¼ 0.176; effect
size, 0.16; Fig. 2A).
There was no signiﬁcant difference in LS mean change at week 6
in the CGI-BP-S depression score for the lurasidone versus placebo
groups (1.36 vs. 1.13; P ¼ 0.095; effect size, 0.20; Fig. 2B). Sta-
tistical superiority for lurasidone versus placebowas observed from
weeks 2 through 5 for change in the MADRS, and from weeks 3
through 5 for change in CGI-BP-S.
The proportion of patients whomet a priori responder criteria at
LOCF endpoint for the lurasidone and placebo groups, respectively,
Completed Study,  N=148 (82.2%)
Lurasidone 20-120 mg (+ Li / VPA), N=180
Current adjunctive (no run-in), N=65
Run-in adjunctive, N=115
Placebo (+ Li / VPA), N=176
Current adjunctive (no run-in), N=72
Run-in adjunctive, N=104
Completed Study,  N=140 (79.5%)
6-week DB treatment6-week DB treatment
Screened for eligibility
(N=748)
Randomized without 
Li / VPA run-in
(N=137)
Randomized with 
Li / VPA run-in
(N=219)
Up to 8 weeks of run-in 
adjunctive treatment
Screen failures, N=516
(Includes patients who entered run-in 
period but were not randomized, N=124)
Total discontinued , N=32 (17.8%)
Insufficient response, N=2 (1.1%)
Adverse events, N=11 (6.1%)
Withdrew consent, N=5 (2.8%)
Miscellaneous, N=14 (7.8%)
Total discontinued , N=36 (20.5%)
Insufficient response, N=6 (3.4%)
Adverse events, N=5 (2.8%)
Withdrew consent, N=9 (5.1%)
Miscellaneous, N=16 (9.1%)
Fig. 1. Patient disposition.
Table 1
Baseline demographic and clinical characteristics (intent-to-treat population).
Characteristic Lurasidone (þLithium/
Valproate)
(N ¼ 176)
Placebo (þLithium/Valproate)
(N ¼ 166)
N % N %
Female 91 51.7 93 56.0
Race
White 113 64.2 108 65.1
Black/African-American 21 11.9 17 10.2
Asian 26 14.8 27 16.3
Other 16 9.1 14 8.4
Hispanic/Latino ethnicity 29 16.5 22 13.3
History of rapid cycling (4 episodes in past 12 months) 32 18.2 21 12.7
Adjunctive mood stabilizer, n (%)
Lithium 56 31.8 57 34.3
Valproate 120 68.2 109 65.7
Mean SD Mean SD
Age, years 43.1 11.9 44.1 12.0
Age of onset of diagnosis, years 28.8 12.1 29.8 12.8
Duration of current episode, weeks 11.9 8.6 15.1 11.7
Baseline scores
MADRS 29.1 4.9 29.1 4.7
CGI-BP-S 4.5 0.7 4.4 0.6
HAM-A 15.8 5.6 15.8 5.7
YMRS 3.6 2.7 3.8 2.9
QIDS-SR16 14.2 3.8 14.5 3.5
Q-LES-Q-SF 35.3 13.3 35.1 11.3
SDS 18.8 5.6 19.2 5.4
MADRS ¼Montgomery-Åsberg Depression Rating Scale; CGI-BP-S ¼ Clinical Global Impression e Bipolar Version e Severity of Illness depression score; HAM-A ¼ Hamilton
Rating Scale for Anxiety; YMRS ¼ Young Mania Rating Scale; QIDS-SR16: 16-item Quick Inventory of Depressive Symptomatology e Self Report; Q-LES-Q-SF: Quality of Life
Enjoyment and Satisfaction Questionnaire e Short Form; SDS ¼ Sheehan Disability Scale.
T. Suppes et al. / Journal of Psychiatric Research 78 (2016) 86e93 89was 39% vs. 31% (P ¼ 0.112; NNT ¼ 13); the proportion who met
remission criteria at LOCF endpoint was 34% vs. 28% (P ¼ 0.227;
NNT ¼ 18).
For secondary efﬁcacy measures, LS mean changes from base-
line to LOCF endpoint for lurasidone and placebo groups, respec-
tively, were as follows: QIDS-SR16 (5.5 vs. 4.3; P ¼ 0.024); HAM-
A score (5.7 vs. 3.8; P ¼ 0.002); Q-LES-Q-SF (þ14.3 vs. þ10.2;
P ¼ 0.038); and SDS total score (5.4 vs. 5.4; P ¼ 0.992).
3.3. Effect of adjunctive treatment status at the time of enrollment
In a pre-planned analysis, improvement in placebo-subtractedMADRS total score at study endpoint was signiﬁcantly larger for
patients adequately treated with lithium or valproate prior to
screening (non-run-in cohort) compared to the cohort who
required prospective treatment with lithium or valproate to qualify
for randomization (run-in cohort; LS mean difference in endpoint
change scores, 4.6; P ¼ 0.009; Fig. 3).
A comparison of baseline characteristics for the non-run-in
cohort versus the run-in cohort found small differences in several
variables at study baseline including the proportion of males (50.8%
vs 43.3%), mean age (45.0 vs 42.7 years), the proportion receiving
valproate (72.0% vs 63.8%), the proportionwith rapid cycling (12.1%
vs 17.6%), and the reported age at initial bipolar diagnosis (31.9 vs
Fig. 2. LS mean change from baseline in efﬁcacy measures (MMRM analysis; ITT population) (A) MADRS total score (B) CGI-BP-S score.
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baseline (29.0 vs 29.2), as were the mean HAM-A (15.8 vs 15.7) and
YMRS (3.3 vs 4.0) scores.
Among patients who required a prospective run-in prior to
randomization (N ¼ 341), 64.2% met study inclusion criteria
following the run-in and were randomized. The remaining 35.8% of
run-in patients were excluded, primarily due to no longer meeting
MADRS severity criteria for randomization. Consistent with this,
patients whowere randomized showed signiﬁcantly less screen-to-
baseline improvement in the MADRS total score compared with
patients who were not randomized (1.1 vs. 8.6; P < 0.001).3.4. Safety
Overall, treatment-emergent adverse events reported with an
incidence 5% in the lurasidone group, and more frequent than
placebo, were akathisia (14.1% vs. 5.3%), somnolence (11.9% vs.
4.7%), extrapyramidal symptoms (12.4% vs. 7.6%), nausea (10.2% vs.
9.4%), and diarrhea (7.9% vs. 5.8%; Table 2A). The proportion of
treatment-emergent adverse events rated as “severe” in thelurasidone and placebo groups, respectively, was 9.0% and 5.3%. The
incidence of serious events was low, and similar between the lur-
asidone (N ¼ 5, 2.8%) and placebo (N ¼ 3, 1.8%) groups. There were
no deaths in the study. The proportion of patients who dis-
continued due to adverse events was 6.1% in the lurasidone group
and 2.8% in the placebo group (Fig. 1).
Treatment-emergent mania (protocol-deﬁned) was reported for
1 patient in the lurasidone group and 3 patients in the placebo
group. LS mean change in YMRS total score at week 6 was similar
for lurasidone vs. placebo (0.9 vs. 0.6). Based on the C-SSRS,
treatment with lurasidone or placebo was associated with similar
rates of treatment-emergent suicidal ideation or behavior (9.7% vs.
12.0%); there were no completed suicides.
The incidence of extrapyramidal symptom-related adverse
events was 12.4% in the lurasidone group and 7.6% in the placebo
group; 6.8% of the lurasidone group and 3.5% of the placebo group
received anticholinergic medication for acute extrapyramidal
symptoms. Treatment with lurasidone (vs. placebo) was associated
with small mean changes at LOCF endpoint in the BARS global score
(þ0.1 vs. 0.0) and the SAS 10-item mean score (0.0 vs. 0.0); a shift
Fig. 3. LS mean change from baseline in MADRS total score for the non-run-in vs. run-in ascertainment cohorts.
Table 2A
Safety and tolerability parameters (safety population). Adverse events (incidence
5%, with incidence greater for the lurasidone group versus placebo).
Lurasidone
(þLithium/
Valproate)
(N ¼ 177)
Placebo (þLithium/
Valproate)
(N ¼ 171)
N % N %
At least one event 121 68.4 105 61.4
Akathisia 25 14.1 9 5.3
Somnolencea 21 11.9 8 4.7
Parkinsonismb 20 11.3 13 7.6
Nausea 18 10.2 16 9.4
Diarrhea 14 7.9 10 5.8
a Somnolence: hypersomnia, sedation, somnolence.
b Parkinsonism ¼ cogwheel rigidity, drooling, parkinsonism, psychomotor
retardation, tremor.
Table 2B
Safety and tolerability parameters (safety population). Change from baseline in
weight and laboratory parameters at LOCF endpoint.
Lurasidone (þLithium/
Valproate)
(N ¼ 177)
Placebo (þLithium/
Valproate)
(N ¼ 171)
Mean (SD) Median Mean (SD) Median
Weight, kg 0.0 (2.4) 0.0 þ0.2 (1.7) 0.0
Total cholesterol, mg/dL 3.3 (26.9) 4.0 2.0 (29.2) 2.5
LDL cholesterol, mg/dL 3.4 (23.2) 3.5 2.5 (24.7) 0.0
Triglycerides, mg/dL þ0.4 (56.3) þ1.0 3.1 (72.1) 1.0
Glucose, mg/dL þ1.4 (14.9) 0.0 1.4 (14.4) 0.5
HbA1c, % 0.0 (0.3) 0.0 0.0 (0.2) 0.0
Insulin, mU/L þ1.9 (12.2) þ0.3 2.5 (15.9) 0.2
Prolactin, ng/mL þ4.3 (13.9) þ1.8 0.6 (10.3) 0.1
Prolactin, Males þ3.2 (5.7) þ1.8 1.5 (5.5) 0.4
Prolactin, Females þ5.3 (18.5) þ2.1 þ0.2 (12.9) þ0.5
Both conﬁrmed and non-conﬁrmed fasting values are presented for metabolic pa-
rameters. HbA1c: glycosylated hemoglobin; LDL: low-density lipoprotein.
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patients (2.3%) in the lurasidone group, and in 2 patients in the
placebo group (1.2%), across all 6 weeks of the study.
The proportion of patients treated with anxiolytics was 17.5% forthe lurasidone group and 20.5% for the placebo group; the pro-
portion treated with hypnotics was 22.0% for lurasidone and 28.1%
for placebo.
LOCF endpoint change in weight was similar for the lurasidone
and placebo groups (Table 2B). The proportion of patients with7%
increase in weight during the study was 3.0% in the lurasidone
group and 0% in the placebo group; the proportion with 7%
decrease in weight was 3.0% in the lurasidone group and 0% in the
placebo group. Mean LOCF endpoint change inwaist circumference
was similar between the lurasidone and placebo groups (0.2 cm
vs. þ0.6 cm).
There were no clinically signiﬁcant between-group, treatment-
emergent differences in vital signs, ECG, or laboratory measures
(Table 2B).
4. Discussion
In this short-term study of patients with bipolar depression,
signiﬁcant improvement was not demonstrated for lurasidone,
adjunctive with lithium or valproate, compared with placebo, on
either the MADRS, the primary assessment, or on the CGI-BP-S, the
key secondary assessment at theweek 6 study endpoint. Signiﬁcant
improvement in depressive symptoms was observed for lurasidone
compared with placebo on the MADRS fromweek 2 through 5, and
on the CGI-BP-S from week 3 through 5. Signiﬁcant improvement
was also observed on the QIDS-SR16, a well-validated patient-re-
portedmeasure of depressive symptomatology, and onmeasures of
anxiety (HAM-A) and quality of life (Q-LES-Q) at LOCF-endpoint.
A prior adjunctive study of lurasidone in the treatment of bi-
polar depression demonstrated signiﬁcant efﬁcacy at 6 weeks on
both the MADRS (primary) and CGI-BP-S (key secondary) outcomes
(Loebel et al., 2014a). It is worth considering if differences in the
design of the prior and current adjunctive treatment studies may
have contributed to the ﬁndings reported here. Unlike the previous
adjunctive study (Loebel et al., 2014a), the current study permitted
a prospective run-in phase to allow patients not currently (or
partially) treated with a mood stabilizer to complete at least 28
days of treatment with lithium or valproate prior to randomization.
The availability of both prospective run-in and non-run-in (retro-
spective) cohorts, allowed for a pre-planned within-study
T. Suppes et al. / Journal of Psychiatric Research 78 (2016) 86e9392comparison of the effect of these two ascertainment methods on
treatment outcome. We observe that the difference in placebo-
adjusted endpoint MADRS change scores was signiﬁcantly larger
for the non-run-in versus run-in cohort. The statistical difference
between the two ascertainment cohorts is striking given the
smaller sample sizes for this secondary analysis.
Evidence from two meta-analyses (Nelson and Papakostas,
2009; Iovieno and Papakostas, 2012) suggest that use of a pro-
spective lead-in phase does not improve the magnitude of treat-
ment response in unipolar depression trials utilizing adjunctive
designs. In the current study, use of a prospective run-in period was
associated with a smaller treatment effect size for lurasidone
compared with a previous, similarly designed, lurasidone adjunc-
tive trial in bipolar depression which did not utilize a prospective
run-in period (effect size, 0.16 vs. 0.34, respectively; Loebel et al.,
2014a). Therefore, this study provides preliminary evidence that
use of a prospective run-in period may, in some circumstances,
reduce treatment effect sizes compared to retrospective ascer-
tainment designs with no run-in period.
For patients in the run-in cohort in the current trial, the median
duration of treatment with lithium and valproate (4.4 and 7.5
months, respectively), was notably longer than the prospective
run-in period required to achieve at least 28 days of treatment with
at least one therapeutic blood level. A possible explanation for the
smaller effect size observed in the current study (vs. the prior
adjunctive study; Loebel et al., 2014a) may be that the prospective
run-in period prior to randomization was too short to achieve the
full effect of treatment with lithium or valproate, thus resulting in
continued improvement post-randomization. Similar ﬁndings have
been reported in a previous unipolar depression study in which
mianserin or placebo was added to sertraline after an open-label
run-in period that consisted of 4 weeks of treatment with a
50 mg/d dose, followed by 2 weeks of treatment with a 100 mg/
d dose (Licht and Qvitzau, 2002). No difference in improvement in
depressive symptoms in the adjunctive mianserin vs. placebo
treatment groups was found in the study. We note that unassessed
demographic and clinical differences (e.g., family history of psy-
chiatric illness) may have contributed to some of the observed
variation in treatment outcome for the run-in vs. non-run-in
cohorts.
Even in bipolar depression studies which do not utilize a pro-
spective run-in period, smaller effect sizes are typically reported for
adjunctive therapy compared with monotherapy trials (Cerullo and
Strakowski, 2013). In some sense this could be expected since
concomitant use of lithium or valproate may produce some anti-
depressant effects in patients with bipolar depression, as reviewed
in a recent meta-analysis (Selle et al., 2014). Both the current
adjunctive therapy study, as well as the prior adjunctive study
(Loebel et al., 2014a) found smaller endpoint effect sizes for lur-
asidone compared with a monotherapy study (0.16 and 0.34,
respectively, vs. 0.51; Loebel et al., 2014).
Short-term treatment with lurasidone in the current study was
associated with minimal effect on weight, lipids, and measures of
glycemic control. No new safety concerns were identiﬁed in the
current study; and the safety and tolerability proﬁle of lurasidone
was found to be similar to what has been previously reported in
trials of patients with schizophrenia (Nakamura et al., 2009;
Meltzer et al., 2011; Nasrallah et al., 2015) and bipolar depression
(Loebel et al., 2014, 2014a).
The diagnosis of bipolar disorder carries with it an increased risk
of metabolic syndrome and cardiovascular disease (Goldstein et al.,
2009; Vancampfort et al., 2013). The reduced cardiometabolic risk
of lurasidone relative to selected other atypical antipsychotics may
represent an important consideration in treatment choice and
clinical decision-making in the population studied.A limitation of the current study relates to the clinical popula-
tion. We enrolled only patients with bipolar I depression, and
therefore the extent to which these ﬁndings generalize to patients
with bipolar II depression is not known. In addition, the run-in and
non-run-in cohorts were not ascertained on a randomized basis.
In summary, in this short-term study involving patients with
bipolar I depression, signiﬁcant improvement was not demon-
strated for lurasidone, adjunctive with lithium or valproate,
compared with placebo, on the primary (MADRS), or key secondary
(CGI-BP-S) efﬁcacy assessments at the week 6 study endpoint.
Improvement in MADRS score for lurasidone vs. placebo at study
endpoint was signiﬁcantly larger for patients adequately treated
with lithium or valproate prior to screening (non-run-in cohort)
compared to the cohort treated prospectively with lithium or val-
proate prior to randomization (run-in cohort). For the total sample,
signiﬁcant improvement in depressive symptoms was observed for
lurasidone compared with placebo on the MADRS from week 2
through 5, and on the CGI-BP-S fromweek 3 through 5. Signiﬁcant
endpoint improvement was also observed on the QIDS-SR16, and on
measures of anxiety (HAM-A) and quality of life (Q-LES-Q).
Consistent with previous study results, short-term treatment
with lurasidone was associated with minimal effect on weight,
lipids, and measures of glycemic control.
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